Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine

Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, James F. Simon, Amanda Hagen, Steven M. Gordon
doi: https://doi.org/10.1101/2022.12.17.22283625

Article Information

doi 
https://doi.org/10.1101/2022.12.17.22283625
History 
  • December 19, 2022.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Nabin K. Shrestha1,*,
  2. Patrick C. Burke2,
  3. Amy S. Nowacki3,
  4. James F. Simon4,
  5. Amanda Hagen5 and
  6. Steven M. Gordon1,†
  1. 1Departments of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA
  2. 2Infection Prevention, Cleveland Clinic, Cleveland, Ohio, USA
  3. 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA
  4. 4Enterprise Business Intelligence, Cleveland Clinic, Cleveland, Ohio, USA
  5. 5Occupational Health, Cleveland Clinic, Cleveland, Ohio, USA
  1. ↵*Correspondence:
    N. K. Shrestha, 9500 Euclid Avenue / G-21, Cleveland, OH 44195, USA (shrestn{at}ccf.org)
  2. ↵†Alternate corresponding author:
    S. M. Gordon, MD, 9500 Euclid Avenue / G-21, Cleveland, OH 44195, USA (gordons{at}ccf.org)
Back to top
Posted December 19, 2022.
Download PDF
Data/Code
Email
Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine
Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, James F. Simon, Amanda Hagen, Steven M. Gordon
medRxiv 2022.12.17.22283625; doi: https://doi.org/10.1101/2022.12.17.22283625
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area